{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:25:52Z","timestamp":1786926352701,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RO1NSNS45748"],"award-info":[{"award-number":["RO1NSNS45748"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.taap.2017.04.004","type":"journal-article","created":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T17:31:43Z","timestamp":1491672703000},"page":"34-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Pre-clinical therapeutic development of a series of metalloporphyrins for Parkinson's disease"],"prefix":"10.1016","volume":"326","author":[{"given":"Li-Ping","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Fulton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer N.","family":"Pearson-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2017.04.004_bb0005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1006\/exnr.2000.7525","article-title":"Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP","volume":"167","author":"Andreassen","year":"2001","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.taap.2017.04.004_bb0010","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1073\/pnas.95.13.7659","article-title":"Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)","volume":"95","author":"Ara","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2017.04.004_bb0015","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1016\/0006-2952(84)90682-8","article-title":"The possible relation of glutathione, melanin and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson's disease","volume":"33","author":"Bannon","year":"1984","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.taap.2017.04.004_bb0020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/35072550","article-title":"Experimental models of Parkinson's disease","volume":"2","author":"Beal","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.taap.2017.04.004_bb0025","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1749-6632.2003.tb07470.x","article-title":"Mitochondria, oxidative damage, and inflammation in Parkinson's disease","volume":"991","author":"Beal","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.taap.2017.04.004_bb0030","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1471-4159.1990.tb03143.x","article-title":"Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid","volume":"55","author":"Beal","year":"1990","journal-title":"J. Neurochem."},{"key":"10.1016\/j.taap.2017.04.004_bb0035","doi-asserted-by":"crossref","first-page":"46017","DOI":"10.1074\/jbc.M105564200","article-title":"Nitration and inactivation of tyrosine hydroxylase by peroxynitrite","volume":"276","author":"Blanchard-Fillion","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2017.04.004_bb0040","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1124\/jpet.107.132134","article-title":"Inhibition of mitochondrial hydrogen peroxide production by lipophilic metalloporphyrins","volume":"324","author":"Castello","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2017.04.004_bb0045","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1359-6446(04)03139-3","article-title":"Catalytic antioxidants: a radical approach to new therapeutics","volume":"9","author":"Day","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.taap.2017.04.004_bb0050","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1006\/taap.1996.0201","article-title":"A metalloporphyrin superoxide dismutase mimetic protects against paraquat-induced lung injury in vivo","volume":"140","author":"Day","year":"1996","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2017.04.004_bb0055","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0891-5849(98)00261-5","article-title":"Metalloporphyrins are potent inhibitors of lipid peroxidation","volume":"26","author":"Day","year":"1999","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.taap.2017.04.004_bb0060","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/0028-3908(86)90205-4","article-title":"Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse","volume":"25","author":"Ferraro","year":"1986","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.taap.2017.04.004_bb0065","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1016\/S0968-0896(02)00153-0","article-title":"Superoxide dismutase mimetics: synthesis and structure-activity relationship study of MnTBAP analogues","volume":"10","author":"Gauuan","year":"2002","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.taap.2017.04.004_bb0070","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0022-3565(25)24767-X","article-title":"Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice","volume":"257","author":"Giovanni","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2017.04.004_bb0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.nbd.2012.10.011","article-title":"Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism","volume":"51","author":"Hauser","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.taap.2017.04.004_bb0080","doi-asserted-by":"crossref","first-page":"8126","DOI":"10.1523\/JNEUROSCI.18-20-08126.1998","article-title":"Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation","volume":"18","author":"Hensley","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.taap.2017.04.004_bb0085","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s12035-012-8318-1","article-title":"Defective autophagy in Parkinson's disease: role of oxidative stress","volume":"46","author":"Janda","year":"2012","journal-title":"Mol. Neurobiol."},{"issue":"Suppl. 3","key":"10.1016\/j.taap.2017.04.004_bb0090","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1002\/ana.10483","article-title":"Oxidative stress in Parkinson's disease","volume":"53","author":"Jenner","year":"2003","journal-title":"Ann. Neurol."},{"issue":"Suppl","key":"10.1016\/j.taap.2017.04.004_bb0095","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1002\/ana.410320714","article-title":"Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group","volume":"32","author":"Jenner","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.taap.2017.04.004_bb0100","article-title":"Mitochondria-targeted antioxidants for treatment of Parkinson's disease: Preclinical and clinical outcomes","author":"Jin","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.taap.2017.04.004_bb0105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0378-4347(01)00531-X","article-title":"High-performance liquid chromatography with spectrophotometric and electrochemical detection of a series of manganese(III) cationic porphyrins","volume":"767","author":"Kachadourian","year":"2002","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.taap.2017.04.004_bb0110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bcp.2003.08.036","article-title":"Flavin-dependent antioxidant properties of a new series of meso-N,N\u2032-dialkyl-imidazolium substituted manganese(III) porphyrins","volume":"67","author":"Kachadourian","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.taap.2017.04.004_bb0115","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0896-6273(03)00126-0","article-title":"Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease","volume":"37","author":"Kaur","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.taap.2017.04.004_bb0120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1006\/nbdi.1998.0191","article-title":"Manganese superoxide dismutase overexpression attenuates MPTP toxicity","volume":"5","author":"Klivenyi","year":"1998","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.taap.2017.04.004_bb0125","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/j.1471-4159.2004.02567.x","article-title":"Iron-sulfur enzyme mediated mitochondrial superoxide toxicity in experimental Parkinson's disease","volume":"90","author":"Liang","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.taap.2017.04.004_bb0130","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0306-4522(00)00397-3","article-title":"Mitochondrial superoxide production in kainate-induced hippocampal damage","volume":"101","author":"Liang","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.taap.2017.04.004_bb0135","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1523\/JNEUROSCI.0019-07.2007","article-title":"An orally active catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in vivo","volume":"27","author":"Liang","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.taap.2017.04.004_bb0140","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/70978","article-title":"Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease","volume":"5","author":"Liberatore","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.taap.2017.04.004_bb0145","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1523\/JNEUROSCI.21-13-04582.2001","article-title":"Neuroprotection from delayed postischemic administration of a metalloporphyrin catalytic antioxidant","volume":"21","author":"Mackensen","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.taap.2017.04.004_bb0150","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/S0021-9258(19)45228-9","article-title":"The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase","volume":"247","author":"Misra","year":"1972","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2017.04.004_bb0155","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.tips.2016.06.007","article-title":"Targeting oxidative stress in central nervous system disorders","volume":"37","author":"Patel","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.taap.2017.04.004_bb0160","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0165-6147(99)01336-X","article-title":"Metalloporphyrin class of therapeutic catalytic antioxidants","volume":"20","author":"Patel","year":"1999","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.taap.2017.04.004_bb0165","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0896-6273(00)80052-5","article-title":"Requirement for superoxide in excitotoxic cell death","volume":"16","author":"Patel","year":"1996","journal-title":"Neuron"},{"key":"10.1016\/j.taap.2017.04.004_bb0170","doi-asserted-by":"crossref","first-page":"34621","DOI":"10.1074\/jbc.274.49.34621","article-title":"Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o\u2032-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease","volume":"274","author":"Pennathur","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2017.04.004_bb0175","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0304-3940(82)90390-1","article-title":"Parkinson's disease: a disorder due to nigral glutathione deficiency?","volume":"33","author":"Perry","year":"1982","journal-title":"Neurosci. Lett."},{"issue":"Suppl. 1","key":"10.1016\/j.taap.2017.04.004_bb0180","first-page":"35","article-title":"Mechanisms of MPTP toxicity","volume":"13","author":"Przedborski","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.taap.2017.04.004_bb0185","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1749-6632.2003.tb07476.x","article-title":"The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease","volume":"991","author":"Przedborski","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.taap.2017.04.004_bb0190","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1523\/JNEUROSCI.12-05-01658.1992","article-title":"Transgenic mice with increased Cu\/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity","volume":"12","author":"Przedborski","year":"1992","journal-title":"J. Neurosci."},{"key":"10.1016\/j.taap.2017.04.004_bb0195","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1073\/pnas.93.10.4565","article-title":"Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity","volume":"93","author":"Przedborski","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2017.04.004_bb0200","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1046\/j.1471-4159.2001.00174.x","article-title":"Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease","volume":"76","author":"Przedborski","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.taap.2017.04.004_bb0205","first-page":"83","article-title":"Free radical and nitric oxide toxicity in Parkinson's disease","volume":"91","author":"Przedborski","year":"2003","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.taap.2017.04.004_bb0210","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","article-title":"Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline","volume":"59","author":"Shults","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.taap.2017.04.004_bb0215","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ana.410360305","article-title":"Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia","volume":"36","author":"Sian","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.taap.2017.04.004_bb0220","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0014-2999(86)90444-9","article-title":"The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice","volume":"129","author":"Sonsalla","year":"1986","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.taap.2017.04.004_bb0225","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/S0968-0896(03)00272-4","article-title":"Superoxide dismutase mimetics. Part 2: synthesis and structure-activity relationship of glyoxylate- and glyoxamide-derived metalloporphyrins","volume":"11","author":"Trova","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.taap.2017.04.004_bb0230","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biocel.2006.07.001","article-title":"Free radicals and antioxidants in normal physiological functions and human disease","volume":"39","author":"Valko","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.taap.2017.04.004_bb0235","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0166-2236(98)01362-9","article-title":"Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias","volume":"22","author":"West","year":"1999","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.taap.2017.04.004_bb0240","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1523\/JNEUROSCI.22-05-01763.2002","article-title":"Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease","volume":"22","author":"Wu","year":"2002","journal-title":"J. Neurosci."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X17301539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X17301539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T21:32:44Z","timestamp":1750195964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X17301539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":48,"alternative-id":["S0041008X17301539"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2017.04.004","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-clinical therapeutic development of a series of metalloporphyrins for Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2017.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}